Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888536 | 0.87 | CTSL (0.35) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL1965623 | 0.81 | BTK (0.38) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL15888207 | 0.80 | CTSL (0.37) | BTKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL29395889 | 0.80 | CA1 (0.34) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL29399267 | 0.75 | GAA (0.35) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL12070311 | 0.74 | GAA (0.39) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL29398236 | 0.72 | CTSL (0.40) | CTSLMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL18878390 | 0.72 | CTSL (0.39) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL22026374 | 0.72 | MEN1 (0.38) | BTKCTSLGAAMEN1MAPK1 | |
| SCHEMBL1968260 | 0.71 | EPHX1 (0.35) | CTSLGAAMEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | BTK 2783/4885CTSL 5/4885GAA 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.